Chiesi

RETAVASE

Manufacturer:

Chiesi

Retavase HCPCS:

J2993

HCPCS Code Descriptor:

Injection, reteplase, 18.1 mg

Category:

J Code

Retavase NDCs:

10122-0141-02

Primary Type:

Thrombolytic

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

10122-0141-02

About Retavase:

RETAVASE is a Thrombolytic drug manufactured by Chiesi and administered via the Intravenous route of administration. The J Code: J2993 is aligned to the drug RETAVASE.

ACCESS PRICING AND MORE BY REGISTERING

J2993 Added Date:

January 1, 2001

J2993 Effective Date:

January 1, 2001

J2993 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Retavase billing and coding information.
Our team did not identify a source for Retavase patient assistance information. Please reach out to our team if you feel that this is a mistake.
RETAVASE prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for RETAVASE. Please check back in a few weeks.